Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy

Scandinavian Journal of Rheumatology

Volumn 35, Issue 2, 2006, Pages 107-111

  Dahlqvist, S Rantapää ^a   Engstrand, S ^a   Berglin, E ^a   Johnson, O ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; DISEASE DURATION; FEMALE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646492303     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740500474578     Document Type: Article

References (19)

1. Haskard DO. Accelerated atherosclerosis in inflammatory rheumatic diseases. Scand J Rheumatol 2004;33:281-92.
2. van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
3. Criqui MH, Golomb BA. Epidemiologic aspects of lipids abnormalities. Am J Med 1998;105:48S-57S.
4. Rantapaa-Dahlqvist S, Wallberg Jonsson S, Dahlen G. Lipoprotein(a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991;50:36-8.
5. Boers M, Nurmohamed MT, Doelman CJA, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5.
6. Wallberg-Jonsson S, Uddhammar A, Dahlen G, Rantapaa-Dahlqvist S. Lipoprotein(a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Scand J Clin Lab Invest 1995;55:309-15.
7. McDevitt H, Munson S, Ettinger R, Wu A. Multiple roles for tumor necrosis factor-α and lymphotoxin α/β in immunity and autoimmunity. Arthritis Res 2002;4, (Suppl 3):141-52.
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
9. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004;24:2137-42.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Prevoo MLL, van't Hof MA, Kuper HH, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8.
12. Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002;114:1004-7.
13. Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL, et al. Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5.
14. Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-5.
15. Park Y-B, Choi HK, Kim M-Y, Lee W-K, Song J, Kim D-K, et al. Effects of anti-rheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002;113:188-93.
16. Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004;15:269-78.
17. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-18.
18. Sethi JK, Hotamisligil GS. The role of TNF in adipocyte metabolism. Cell Dev Biol 1999;10:19-29.
19. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5.